Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000735022 | SCV000863209 | uncertain significance | not provided | 2018-08-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001467061 | SCV001671078 | likely benign | Cystic fibrosis | 2024-03-07 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001467061 | SCV001821997 | likely benign | Cystic fibrosis | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001467061 | SCV002624348 | likely benign | Cystic fibrosis | 2020-07-08 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001833601 | SCV002080134 | likely benign | CFTR-related disorder | 2018-05-17 | no assertion criteria provided | clinical testing |